

AstraZeneca Pharma India Ltd and Sun Pharmaceuticals Industries Ltd enter distribution agreement for ticagrelor in India

Tuesday, 2 June 2015

AstraZeneca Pharma India Limited (AZPIL) (BSE : 506820, NSE : ASTRAZEN, AZPIL) and Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharma) today announced that AZPIL and Sun Pharma have entered into a distribution services agreement for AstraZeneca's brand "Axcer®", a new brand of ticagrelor, a drug used for the treatment of acute coronary syndrome (ACS) in India. AZPIL already has a brand under the trademark "Brilinta®", for the ticagrelor molecule, launched and marketed by AZPIL in India since 2012.

Sanjay Murdeshwar, Managing Director, AstraZeneca Pharma India Limited said, "We are pleased to collaborate with Sun Pharmaceuticals to bring this innovative treatment solution to a larger number of ACS patients in India. Ticagrelor works by preventing the formation of new blood clots and maintains blood flow in the body, helping reduce a patient's risk of another heart attack or cardiovascular-related death."

Abhay Gandhi, CEO - India Business, Sun Pharma commenting on the partnership said, "We are happy to collaborate with AstraZeneca to provide customers access to this latest generation treatment option for ACS. Such collaborations are also a part of our stated policy of becoming the partner of choice for promotion and distribution of innovative pharmaceutical products in the country."

Sun Pharma will be promoting and distributing the "Axcer®" brand in India. This collaboration enables AstraZeneca to expand usage of this molecule through wider reach to physicians and thereby benefiting a greater number of ACS patients. It strengthens Sun Pharma's cardiology portfolio with the addition of a new patented therapy.

NOTES TO EDITORS

About Ticagrelor

Ticagrelor is a direct-acting, selective and reversibly binding P2Y₁₂ receptor antagonist in a chemical class called cyclo-pentyl-triazolo-pyrimidines (CPTPs). Ticagrelor works by inhibiting platelet activation.

Ticagrelor (90mg) is indicated to reduce the rate of thrombotic CV events in patients with ACS (unstable angina [UA], non-ST-elevation myocardial infarction [NSTEMI], or ST-elevation myocardial infarction [STEMI]). Ticagrelor has been shown to reduce the rate of a combined end point of CV death, MI, or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with percutaneous coronary intervention, it also reduces the rate of stent thrombosis.

About Sun Pharmaceuticals

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun

Pharma's global presence is supported by 45 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. The pro forma consolidated revenues for 12 months ending December 2014 are at US\$4.5 billion, of which US contributes

US\$2.2 billion. In India, the company enjoys leadership across 12 different classes of doctors with 30 brands featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging markets covers over 50 countries and 6 markets in Western Europe. Its Global Consumer Healthcare business is ranked amongst Top 10 across 4 global markets. Its API business footprint is strengthened through 11 world class API manufacturing facilities across the globe. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising 1800 scientists and R&D investments of over 6% of annual revenues. For further information please visit www.sunpharma.com

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit www.astrazeneca.com

CONTACT

Varsha Das
Corporate Communications
Email: Varsha.das@edelman.com
Mobile +91. 9741752900
Landline: 080.67748497

Sharon Menezes
Corporate Communications
Email: sharon.menezes@edelman.com
Mobile +91.9632664401
Landline:080.33499143